Serum HER2 Levels Determined by Two Methods in Patients With Metastatic Breast Cancer

International Journal of Clinical Oncology - Japan
doi 10.1007/s10147-011-0253-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Work Productivity Activity Impairment Loss of Patients With HER2 Metastatic Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Association of Serum Progranulin Levels With Disease Progression and Decreased Survival in Metastatic Breast Cancer Patients

Clinical Breast Cancer
Cancer ResearchOncology
2019English

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Therapy Landscape in Patients With Metastatic HER2-Positive Breast Cancer: Data From the PRAEGNANT Real-World Breast Cancer Registry

Cancers
Cancer ResearchOncology
2018English

HER2-Orientated Therapy in Early and Metastatic Breast Cancer

Breast Care
SurgeryOncology
2016English

Retrospective Analysis of HER2 Therapy Interruption in Patients Responding to the Treatment in Metastatic HER2+ Breast Cancer

ESMO Open
Cancer ResearchOncology
2017English

Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients

Clinical Cancer Research
Cancer ResearchOncology
2004English

Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer

Journal of Cancer
Oncology
2020English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy